drugset
drugset / Trial / NCT06826118

Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma

NCT06826118 ↗

Phase 2 Recruiting 30 enrolled The First Affiliated Hospital of Xiamen University
NaSingle-groupOpen-labelTreatment

Summary

A prospective collection of data on the treatment of Chinese patients with relapsed/refractory follicular lymphoma (FL) using Axicabtagene Ciloleucel Injection, and evaluation of the efficacy and safety of Axicabtagene Ciloleucel Injection in this treatment.

Timeline

Start
2025-02-08
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Axicabtagene Ciloleucel Cell therapy 1.5 cells/kg Intravenous
Subject Axicabtagene Ciloleucel Cell therapy 2 cells/kg Intravenous
Background Cyclophosphamide Other / unclassified 500 mg/m2 Intravenous
Background Fludarabine Small molecule 30 mg/m2 Intravenous

Indications

follicular lymphoma